lapatinib has been researched along with Cancer of Endometrium in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baker, AM; Bakhouche, BA; Carter, EP; Chelala, C; Chupin, J; Clayton, NS; Cutillas, PR; Fearon, AE; Gadaleta, E; Grose, RP; Jones, JL; Kapitonova, E; Lockley, M; Marshall, JF; Moore, KM; Schmid, P; Tanner, Y; Wang, J; Wilkes, EH | 1 |
| Chang, TC; Chao, A; Chao, AS; Chou, HH; Hsueh, S; Huang, HJ; Lai, CH; Lee, YS; Lin, CY; Wang, TH; Wu, TI | 1 |
| Muggia, F; Teplinsky, E | 1 |
| Abulafia, O; Fischer, EG; Godwin, AK; Gray, H; Hanjani, P; Lankes, HA; Leslie, KK; Rose, PG; Schilder, RJ; Sill, MW; Tewari, K; Walker, JL | 1 |
| Dering, J; Fejzo, MS; Finn, R; Ginther, C; Jiang, SW; Konecny, GE; Podratz, KC; Rahmeh, M; Slamon, DJ; Toft, D; Venkatesan, N; Yang, G | 1 |
1 review(s) available for lapatinib and Cancer of Endometrium
| Article | Year |
|---|---|
Targeting HER2 in ovarian and uterine cancers: challenges and future directions.
Topics: Adenocarcinoma, Mucinous; Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma; Endometrial Neoplasms; Female; Genes, erbB-2; Humans; Lapatinib; Maytansine; Molecular Targeted Therapy; Ovarian Neoplasms; Quinazolines; Trastuzumab; Uterine Neoplasms | 2014 |
1 trial(s) available for lapatinib and Cancer of Endometrium
| Article | Year |
|---|---|
Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; DNA Mutational Analysis; Drug Administration Schedule; Endometrial Neoplasms; Female; Genes, erbB-1; Genetic Markers; Humans; Immunohistochemistry; Lapatinib; Middle Aged; Mutation; Neoplasm Recurrence, Local; Prognosis; Quinazolines; Survival Analysis; Treatment Outcome | 2012 |
3 other study(ies) available for lapatinib and Cancer of Endometrium
| Article | Year |
|---|---|
PHLDA1 Mediates Drug Resistance in Receptor Tyrosine Kinase-Driven Cancer.
Topics: Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Lapatinib; Models, Biological; Phosphoproteins; Protein Kinase Inhibitors; Proteomics; Receptors, Fibroblast Growth Factor; Transcription Factors; Trastuzumab | 2018 |
A dual tyrosine kinase inhibitor lapatinib suppresses overexpression of matrix metallopeptidase 1 (MMP1) in endometrial cancer.
Topics: Antineoplastic Agents; Cell Line, Tumor; Endometrial Neoplasms; Endometrium; ErbB Receptors; Female; Humans; Lapatinib; MAP Kinase Signaling System; Matrix Metalloproteinase 1; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Signal Transduction; Transcription Factor AP-1; Up-Regulation | 2014 |
Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug Screening Assays, Antitumor; Endometrial Neoplasms; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Lapatinib; Oncogene Protein v-akt; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction | 2008 |